Sort
21,281 grants matching “influenza”
Viral Arrays for Biodefense
$996,647W. Ian Lipkin · Columbia University Health Sciences · U01 · FY2006 · AI
Innovative Optical System for Hemagglutination Assays
$996,634Kathy L Rowlen · Indevr, Inc. · R44 · FY2016 · AI
SBIR Phase II: Stable Prophylactic Antibodies
$996,606Arthur Young · Invvax, Inc. · · FY2025 · TIP
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
$996,500Kenneth C Bagley · Orlance, Inc. · R44 · FY2023 · AI
Origin and maturation of protective memory B cell responses against pathogenic viruses in natural infections and upon vaccination.
$995,831Mattia Bonsignori · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Structure-guided neutralizing antibodies developed using EpiVolve technology
$995,774Xiaofeng Li · Abbratech, Inc. · R44 · FY2024 · AI
The Incidence and Etiology of Influenza-Associated Pneumonia in Hospitalized Pers
$995,767Kathryn Margaret Edwards · Vanderbilt University · U18 · FY2010 · IP
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$995,652Richard A Cone · Mucommune, Llc · R44 · FY2021 · AI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses
$995,510Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2015 · AI
Structural study of the HIV1 gp41 coat protein
$995,227Adriaan Bax · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Patterning of Transcription Factor Activity in T cells During Influenza Infection
$995,168Rajat Varma · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Point of Care Detection of Respiratory Viruses
$995,154Michael James Moser · Lucigen Corporation · R44 · FY2012 · AI
Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for a Phase I Trial for Influenza Vaccine.
$995,111Karen Kotloff · University Of Maryland Baltimore · N01 · FY2019 · AI
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
$994,859Arthur P Bertolino · Cytoagents, Inc. · R44 · FY2024 · CA
Innovative Optical System for Hemagglutination Assays
$994,754Kathy L Rowlen · Indevr, Inc. · R44 · FY2017 · AI
Comparative Genomics: Mechanism(s) Against Emerging Infectious Diseases
$994,571Stephen J O'Brien · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
i-AKC: Integrated AIRR Knowledge Commons
$994,460Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2024 · AI
SIMULTANEOUS SCREENING FOR A/H3N2, A/H1N1, A/H5N1 AND B INFLUENZA VIRUSES
$994,286Erica D Dawson · Indevr, Inc. · R44 · FY2011 · AI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses
$993,983Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2016 · AI
Skin vaccination and generation of protective lung-tropic memory T cells
$993,763Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2024 · AI
Enabling risk-based testing through characterization of environmentally-Induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19
$993,529Florence Burleson · · N01 · FY2021 · ES
Development of highly potent human monoclonal for RSV immunoprophylaxis
$993,353Ellen Monson · Mapp Biopharmaceutical, Inc. · SB1 · FY2025 · AI
Preclinical development of a potent D-peptide RSV inhibitor
$992,263Brett D Welch · Navigen, Inc. · R44 · FY2016 · AI
B-cell repertoire analysis in influenza vaccination and infection
$992,119Hua-Xin Liao · Boston Children'S Hospital · P01 · FY2015 · AI
Agonists of the RIG-I Innate Immune Pathway
$992,047Shawn Patrick Iadonato · Kineta, Inc. · R44 · FY2011 · AI